Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Apr;79(11-12):1692–1701. doi: 10.1038/sj.bjc.6690270

A novel class of lipophilic quinazoline-based folic acid analogues: cytotoxic agents with a folate-independent locus

L A Skelton 1, M G Ormerod 1, J Titley 1, R Kimbell 1, L A Brunton 1, A L Jackman 1
PMCID: PMC2362793  PMID: 10206279

Abstract

Three lipophilic quinazoline-based aminomethyl pyridine compounds, which differ only in the position of the nitrogen in their pyridine ring, are described. CB300179 (2-pyridine), CB300189 (4-pyridine) and CB30865 (3-pyridine) all inhibited isolated mammalian TS with IC50 values of 508, 250 and 156 nM respectively. CB30865 was the most potent growth inhibitory agent (IC50 values in the range 1– 100 nM for several mouse and human cell types). CB300179 and CB300189 were active in the micromolar range. Against W1L2 cells, CB300179 and CB300189 demonstrated reduced potency in the presence of exogenous thymidine (dThd), and against a W1L2:C1 TS overproducing cell line. In contrast, CB30865 retained activity in these systems. Furthermore, combinations of precursors and end products of folate metabolism, e.g. dThd/hypoxanthine (HX) or leucovorin (LV), did not prevent activity. CB30865 did not interfere with the incorporation of tritiated dThd, uridine or leucine after 4 h. A cell line was raised with acquired resistance to CB30865 (W1L2:R865; > 200-fold), which was not cross-resistant to CB300179 or CB300189. In addition, W1L2:R865 cells were as sensitive as parental cells to agents from all the major chemotherapeutic drug classes. CB300179 and CB300189 induced an S phase accumulation (preventable by co-administration of dThd). No cell cycle redistribution was observed following exposure (4–48 h) to an equitoxic concentration of CB30865. In the NCI anticancer drug-discovery screen, CB30865 displayed a pattern of activity which was not consistent with known anti-tumour agents. These data suggest that CB30865 represents a class of potent potential anti-tumour agents with a novel mechanism of action. © 1999 Cancer Research Campaign

Keywords: ZM198583, CB30865, TS, cell cycle, cross-resistance, folate-independent

Full Text

The Full Text of this article is available as a PDF (190.6 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Charcosset J. Y. Effects of antineoplastic agents on the cell cycle progression. Biol Cell. 1986;58(2):135–138. doi: 10.1111/j.1768-322x.1986.tb00497.x. [DOI] [PubMed] [Google Scholar]
  2. Hook K. E., Nelson J. M., Roberts B. J., Griswold D. P., Leopold W. R. Cell cycle effects of trimetrexate (CI-898). Cancer Chemother Pharmacol. 1986;16(2):116–120. doi: 10.1007/BF00256159. [DOI] [PubMed] [Google Scholar]
  3. Jackman A. L., Alison D. L., Calvert A. H., Harrap K. R. Increased thymidylate synthase in L1210 cells possessing acquired resistance to N10-propargyl-5,8-dideazafolic acid (CB3717): development, characterization, and cross-resistance studies. Cancer Res. 1986 Jun;46(6):2810–2815. [PubMed] [Google Scholar]
  4. Jackman A. L., Boyle F. T., Harrap K. R. Tomudex (ZD1694): from concept to care, a programme in rational drug discovery. Invest New Drugs. 1996;14(3):305–316. doi: 10.1007/BF00194534. [DOI] [PubMed] [Google Scholar]
  5. Jackman A. L., Calvert A. H., Hart L. I., Harrap K. R. Inhibition of thymidylate synthetase by the new quinazoline antifolate, CB 3717; enzyme purification and kinetics. Adv Exp Med Biol. 1984;165(Pt B):375–378. doi: 10.1007/978-1-4757-0390-0_71. [DOI] [PubMed] [Google Scholar]
  6. Jackman A. L., Kelland L. R., Kimbell R., Brown M., Gibson W., Aherne G. W., Hardcastle A., Boyle F. T. Mechanisms of acquired resistance to the quinazoline thymidylate synthase inhibitor ZD1694 (Tomudex) in one mouse and three human cell lines. Br J Cancer. 1995 May;71(5):914–924. doi: 10.1038/bjc.1995.178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Jackman A. L., Kimbell R., Aherne G. W., Brunton L., Jansen G., Stephens T. C., Smith M. N., Wardleworth J. M., Boyle F. T. Cellular pharmacology and in vivo activity of a new anticancer agent, ZD9331: a water-soluble, nonpolyglutamatable, quinazoline-based inhibitor of thymidylate synthase. Clin Cancer Res. 1997 Jun;3(6):911–921. [PubMed] [Google Scholar]
  8. Jackman A. L., Kimbell R., Brown M., Brunton L., Boyle F. T. Quinazoline thymidylate synthase inhibitors: methods for assessing the contribution of polyglutamation to their in vitro activity. Anticancer Drug Des. 1995 Oct;10(7):555–572. [PubMed] [Google Scholar]
  9. Jackman A. L., Kimbell R., Brown M., Brunton L., Harrap K. R., Wardleworth J. M., Boyle F. T. The antitumour activity of ZD9331, a non-polyglutamatable quinazoline thymidylate synthase inhibitor. Adv Exp Med Biol. 1994;370:185–188. doi: 10.1007/978-1-4615-2584-4_40. [DOI] [PubMed] [Google Scholar]
  10. Jackman A. L., Newell D. R., Gibson W., Jodrell D. I., Taylor G. A., Bishop J. A., Hughes L. R., Calvert A. H. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583). Biochem Pharmacol. 1991 Oct 24;42(10):1885–1895. doi: 10.1016/0006-2952(91)90586-t. [DOI] [PubMed] [Google Scholar]
  11. Jackman A. L., Taylor G. A., O'Connor B. M., Bishop J. A., Moran R. G., Calvert A. H. Activity of the thymidylate synthase inhibitor 2-desamino-N10-propargyl-5,8-dideazafolic acid and related compounds in murine (L1210) and human (W1L2) systems in vitro and in L1210 in vivo. Cancer Res. 1990 Sep 1;50(17):5212–5218. [PubMed] [Google Scholar]
  12. Kobayashi H., Takemura Y., Miyachi H., Skelton L., Jackman A. L. Effect of hammerhead ribozyme against human thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitors. Jpn J Cancer Res. 1995 Nov;86(11):1014–1018. doi: 10.1111/j.1349-7006.1995.tb03014.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Lorico A., Toffoli G., Boiocchi M., Erba E., Broggini M., Rappa G., D'Incalci M. Accumulation of DNA strand breaks in cells exposed to methotrexate or N10-propargyl-5,8-dideazafolic acid. Cancer Res. 1988 Apr 15;48(8):2036–2041. [PubMed] [Google Scholar]
  14. Monks A., Scudiero D., Skehan P., Shoemaker R., Paull K., Vistica D., Hose C., Langley J., Cronise P., Vaigro-Wolff A. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. J Natl Cancer Inst. 1991 Jun 5;83(11):757–766. doi: 10.1093/jnci/83.11.757. [DOI] [PubMed] [Google Scholar]
  15. O'Connor B. M., Jackman A. L., Crossley P. H., Freemantle S. E., Lunec J., Calvert A. H. Human lymphoblastoid cells with acquired resistance to C2-desamino-C2-methyl-N10-propargyl-5,8-dideazafolic acid: a novel folate-based thymidylate synthase inhibitor. Cancer Res. 1992 Mar 1;52(5):1137–1143. [PubMed] [Google Scholar]
  16. Paull K. D., Shoemaker R. H., Hodes L., Monks A., Scudiero D. A., Rubinstein L., Plowman J., Boyd M. R. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst. 1989 Jul 19;81(14):1088–1092. doi: 10.1093/jnci/81.14.1088. [DOI] [PubMed] [Google Scholar]
  17. Skelton L. A., Ormerod M. G., Titley J. C., Jackman A. L. Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action. Cytometry. 1998 Sep 1;33(1):56–66. doi: 10.1002/(sici)1097-0320(19980901)33:1<56::aid-cyto7>3.0.co;2-9. [DOI] [PubMed] [Google Scholar]
  18. Stephens T. C., Smith M. N., Waterman S. E., McCloskey M. L., Jackman A. L., Boyle F. T. Use of murine L5178Y lymphoma thymidine kinase mutants for in vitro and in vivo antitumour efficacy evaluation of novel thymidylate synthase inhibitors. Adv Exp Med Biol. 1993;338:589–592. doi: 10.1007/978-1-4615-2960-6_120. [DOI] [PubMed] [Google Scholar]
  19. Taylor G. A., Jackman A. L., Balmanno K., Hughes L. R., Calvert A. H. Estimation of the in vitro and in vivo inhibitory effects of antifolates upon thymidylate synthase (TS) in whole cells. Adv Exp Med Biol. 1989;253B:383–388. doi: 10.1007/978-1-4684-5676-9_56. [DOI] [PubMed] [Google Scholar]
  20. Taylor I. W., Tattersall M. H. Methotrexate cytotoxicity in cultured human leukemic cells studied by flow cytometry. Cancer Res. 1981 Apr;41(4):1549–1558. [PubMed] [Google Scholar]
  21. Twentyman P. R., Luscombe M. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. Br J Cancer. 1987 Sep;56(3):279–285. doi: 10.1038/bjc.1987.190. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Ward W. H., Kimbell R., Jackman A. L. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase. Biochem Pharmacol. 1992 May 8;43(9):2029–2031. doi: 10.1016/0006-2952(92)90646-z. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES